Peitao Zhang
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E-associated thyroid carcinoma.
Journal: Clinical and translational medicine
Published: November 29, 2023
Author Correction: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.
Journal: Nature communications
Published: November 17, 2022
Glucose-induced CRL4COP1-p53 axis amplifies glycometabolism to drive tumorigenesis.
Journal: Molecular cell
Published: August 11, 2022
HSA-MnO2-131I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma.
Journal: Technology in cancer research & treatment
Published: June 15, 2022
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.
Journal: Nature communications
Published: May 31, 2021
Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Journal: The Journal of clinical endocrinology and metabolism
Published: April 29, 2020
Author Correction: H2A.Z facilitates licensing and activation of early replication origins.
Journal: Nature
Published: January 15, 2020
H2A.Z facilitates licensing and activation of early replication origins.
Journal: Nature
Published: December 05, 2018
Last Updated: 09/26/2026